MYCOVIA PHARMACEUTICALS
Mycovia offers passionate about developing breakthrough therapies in women’s health and dermatology.
MYCOVIA PHARMACEUTICALS
Industry:
Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.mycovia.com
Total Employee:
11+
Status:
Active
Contact:
919-467-8539
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Current Employees Featured
Official Site Inspections
http://www.mycovia.com Semrush global rank: 2.2 M Semrush visits lastest month: 8.9 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Mycovia Pharmaceuticals"
Home - Mycovia Pharmaceuticals
At Mycovia, our senses are heightened when it comes to uncomfortable health issues. We make overlooked patients a priority so solving unmet needs becomes a reality. By following this link, …See details»
Our Story - Mycovia Pharmaceuticals
Mycovia’s mission to effect positive change extends beyond the pursuit of therapeutic innovations in biopharmaceuticals. We are committed to making a meaningful impact in our global community, with the development and …See details»
Our Mission - Mycovia Pharmaceuticals
We are committed to making a meaningful impact in our global community, with the development and commercialization of novel molecules, and in our local community, through our charitable …See details»
Mycovia Pharmaceuticals - LinkedIn
Mycovia Pharmaceuticals was formed in 2018 following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management. At Mycovia, we are passionate about developing breakthrough...See details»
Optimized production process leads to new FDA-approved …
Mycovia continues to develop additional compounds to treat a range of rare and common fungal infections, all relying upon the manufacturing process created by the IRP scientists.See details»
Mycovia Pharmaceuticals - Leadership Team - The Org
The Leadership Team at Mycovia Pharmaceuticals drives company strategy and operations, oversees the development and execution of projects, ensures regulatory compliance, and optimizes market access.See details»
Mycovia Pharmaceuticals - The Org
At Mycovia Pharmaceuticals, we are passionate about developing novel drugs in areas of unmet medical need including women’s health, our company’s initial focus.See details»
Mycovia Pharmaceuticals - Crunchbase Company Profile & Funding
Mycovia offers passionate about developing breakthrough therapies in women’s health and dermatology. View contacts for Mycovia Pharmaceuticals to access new leads and connect …See details»
FDA Approves Mycovia Pharmaceuticals’ VIVJOA ... - Business Wire
Apr 28, 2022 · VIVJOA is the first FDA-approved product for Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and …See details»
Our Responsibility - Mycovia Pharmaceuticals
Mycovia’s mission to effect positive change is strengthened by values that are rooted firmly throughout our work. Our company is best supported when all employees, consultants, contractors, vendors, and other collaborators share …See details»
Mycovia Pharmaceuticals Submits New Drug Application to the …
Jun 1, 2021 · With this timeline and pending full FDA approval, Mycovia is preparing for a U.S. launch of oteseconazole in early 2022. Mycovia Pharmaceuticals is a late-stage emerging …See details»
Our Products - Mycovia Pharmaceuticals
Mycovia is committed to equalizing care for patients around the world by advancing novel therapies to address the needs of patients living with overlooked medical conditions in …See details»
Mycovia Pharmaceuticals Announces Positive Topline Results
DURHAM, N.C.–(BUSINESS WIRE)–Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet …See details»
Mycovia Pharmaceuticals Announces U.S. FDA Acceptance and …
Jul 28, 2021 · Mycovia’s NDA for oteseconazole is supported by positive results from three Phase 3 trials – two global VIOLET studies and one U.S.-focused ultraVIOLET study, including more …See details»
Mycovia Pharmaceuticals Inc. - VentureRadar
Website: http://www.mycovia.com. Mycovia Pharmaceuticals is developing therapies to treat yeast and fungal infections. NCBiotech Company Directory. Associated sectors: Small Molecule …See details»
Mycovia Pharmaceuticals Announces U.S. Availability of VIVJOA ...
Jul 18, 2022 · DURHAM, N.C.-- ( BUSINESS WIRE )-- Mycovia Pharmaceuticals, Inc. (“Mycovia”), an emerging biopharmaceutical company dedicated to recognizing and empowering those …See details»
Oteseconazole: First Approval | Drugs - Springer
Jun 17, 2022 · Oteseconazole (VIVJOA™) is an orally administered azole antifungal agent developed by Mycovia Pharmaceuticals for the treatment of fungal infections. It inhibits …See details»
Mycovia Pharmaceuticals Submits New Drug Application to the
Mycovia Pharmaceuticals is a late-stage emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel …See details»
Mycovia Eyes FDA Filing as Yeast Infection Drug Meets Phase 3 …
Antifungal therapies developer Mycovia is preparing to seek FDA approval of its first drug after the compound posted positive results in two late-stage clinical trials. The drug is an experimental …See details»
News - Mycovia Pharmaceuticals
Aug 21, 2023 · Stay up to date with the latest Mycovia news, press releases, and more. If you have any questions or comments regarding media inquiries, please reach out to …See details»